Notably, A485 exposure has also demonstrated the ability to downregulate estrogen receptor protein levels in breast cancer [61], and EP300/CREBBP acetyltransferase inhibition curtails estrogen signaling through FOXA1-bound enhancers [62]. Here, EP300 is linked to breast carcinoma.